Business Description
Bioretec Ltd
SIC : 3841
ISIN : FI4000480454
Total Employee Number:
60Compare
Compare
Traded in other countries / regions
BRETEC.Finland0TN.Germany IPO Date
2022-09-28Description
Bioretec Ltd is a Finnish medical device company that develops bioabsorbable and bioresorbable orthopedic implants for pediatric and adult patients. Its product portfolio includes two main lines: RemeOs, based on a magnesium alloy and hybrid composite that is absorbed and replaced by bone, and Activa, made from fully absorbable biopolymers. These implants, including screws, pins, and nails, are designed to facilitate fracture healing and eliminate the need for removal surgery. The company serves orthopedic surgeons and healthcare providers, with its primary market in Europe and expanding regulatory clearances in the United States. Revenue is generated through the sale of its implant products to hospitals and distributors. Bioretec is listed on the Nasdaq First North Growth Market in Finland.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 27.7 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 7.48 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.4 | |||||
3-Year EBITDA Growth Rate | -40.6 | |||||
3-Year EPS without NRI Growth Rate | -27.4 | |||||
3-Year FCF Growth Rate | -37.2 | |||||
3-Year Book Growth Rate | 34.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 52.25 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.89 | |||||
9-Day RSI | 55.58 | |||||
14-Day RSI | 57.26 | |||||
3-1 Month Momentum % | 2.83 | |||||
6-1 Month Momentum % | 49.18 | |||||
12-1 Month Momentum % | -81.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.18 | |||||
Quick Ratio | 5.35 | |||||
Cash Ratio | 4.78 | |||||
Days Inventory | 910.41 | |||||
Days Sales Outstanding | 146.5 | |||||
Days Payable | 98.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.9 | |||||
Shareholder Yield % | -28.46 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.9 | |||||
Operating Margin % | -206.26 | |||||
Net Margin % | -226.46 | |||||
EBITDA Margin % | -200.21 | |||||
FCF Margin % | -324.93 | |||||
OCF Margin % | -308.35 | |||||
ROE % | -60.73 | |||||
ROA % | -51.11 | |||||
ROIC % | -104.11 | |||||
3-Year ROIIC % | -121.08 | |||||
ROC (Joel Greenblatt) % | -164.81 | |||||
ROCE % | -54.81 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.6 | |||||
PB Ratio | 2.11 | |||||
Price-to-Tangible-Book | 2.74 | |||||
EV-to-EBIT | -4.29 | |||||
EV-to-EBITDA | -4.42 | |||||
EV-to-Revenue | 8.84 | |||||
EV-to-FCF | -3.48 | |||||
Price-to-GF-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 2.74 | |||||
| Price-to-Net-Cash | 2.74 | |||||
Earnings Yield (Greenblatt) % | -23.31 | |||||
FCF Yield % | -27.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Bioretec Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.522 | ||
| EPS (TTM) (€) | -0.031 | ||
| Beta | -3.9425 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.2 | ||
| Volatility % | 198.65 | ||
| 14-Day RSI | 57.26 | ||
| 14-Day ATR (€) | 0.002626 | ||
| 20-Day SMA (€) | 0.02485 | ||
| 12-1 Month Momentum % | -81.89 | ||
| 52-Week Range (€) | 0.0108 - 0.162682 | ||
| Shares Outstanding (Mil) | 1,341.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioretec Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioretec Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-12 | In 171 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-12 13:00 | In 144 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 09:30 | In 144 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 0.03 (+0.00%) | ||
| General meeting for 2026 | 2026-05-08 11:00 | 0.01 (+1.67%) | ||
| Annual report for 2025 | 2026-03-13 | 0.01 (-4.69%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-13 13:00 | 0.04 (-3.02%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-13 09:30 | 0.04 (-3.02%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.16 (-2.97%) | ||
| General meeting for 2025 | 2025-03-21 11:00 | 0.21 (+0.00%) |
Show
Entries
Bioretec Ltd Frequently Asked Questions
What is Bioretec Ltd(OHEL:BRETEC)'s stock price today?
The current price of OHEL:BRETEC is €0.03. The 52 week high of OHEL:BRETEC is €0.16 and 52 week low is €0.01.
When is next earnings date of Bioretec Ltd(OHEL:BRETEC)?
The next earnings date of Bioretec Ltd(OHEL:BRETEC) is 2027-02-12 Est..
Does Bioretec Ltd(OHEL:BRETEC) pay dividends? If so, how much?
Bioretec Ltd(OHEL:BRETEC) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers